Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immucell (ICCC) Short-term Investments (2016 - 2020)

Immucell (ICCC) has disclosed Short-term Investments for 10 consecutive years, with $996495.0 as the latest value for Q4 2020.

  • For the quarter ending Q4 2020, Short-term Investments fell 59.83% year-over-year to $996495.0, compared with a TTM value of $996495.0 through Dec 2020, down 59.83%, and an annual FY2020 reading of $996495.0, down 59.83% over the prior year.
  • Short-term Investments was $996495.0 for Q4 2020 at Immucell, down from $2.0 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $8.7 million in Q2 2019 and bottomed at $489582.0 in Q2 2017.
  • Average Short-term Investments over 4 years is $3.9 million, with a median of $3.0 million recorded in 2017.
  • The sharpest move saw Short-term Investments surged 242.07% in 2016, then tumbled 92.69% in 2017.
  • Year by year, Short-term Investments stood at $5.5 million in 2016, then crashed by 91.06% to $489582.0 in 2017, then soared by 406.71% to $2.5 million in 2019, then tumbled by 59.83% to $996495.0 in 2020.
  • Business Quant data shows Short-term Investments for ICCC at $996495.0 in Q4 2020, $2.0 million in Q3 2020, and $2.0 million in Q2 2020.